Related by context. All words. (Click for frequent words.) 72 SELENA SLEDAI score 70 Crohn Disease Activity 70 ACR# response 68 serologically active SLE 67 seropositive patients 66 CDAI score 66 Index CDAI 66 oxycodone CR 66 NIH CPSI 66 MADRS score 66 CIMZIA ™ 66 serum urate 66 DAS# CRP 65 -#.# mg dL [001] 65 plus methotrexate 65 MCyR 65 PASI scores 65 SELENA SLEDAI 65 achieved ACR# 65 CIMZIA TM 64 HAQ DI 64 ACR# responses 64 atheroma volume 64 splenectomized patients 64 mg BID dose 64 CDAI 64 transaminase elevations 64 baseline HbA1c 64 alanine aminotransferase 63 placebo fluoxetine 63 YMRS 63 SLE Responder Index 63 DAS# [002] 63 -#.# mg dL [002] 63 definite stent thrombosis 63 adalimumab 63 CR nPR 63 lumbar spine BMD 63 serum HBV DNA 63 TEAEs 63 ACR Pedi 63 elevated ALT 63 Secondary endpoints include 63 IBDQ 63 arterial thromboembolic events 63 CCyR 63 extrapyramidal symptoms 63 DAS# remission 63 Secondary endpoints included 63 cytogenetic response 63 hypoglycemic events 63 virologic response 63 IL 1ß 62 Capacity FVC 62 Kaplan Meier estimates 62 Score DAS 62 neutropaenia 62 mTSS 62 hematologic parameters 62 Psoriasis Area 62 belimumab 62 tapentadol ER 62 OAB symptoms 62 desvenlafaxine succinate 62 corticosteroid dose 62 NYHA functional class 62 HbA1C levels 62 ULORIC 62 anemia hemoglobin 62 glycated hemoglobin levels 62 dyslipidaemia 62 APTIVUS r 62 complete cytogenetic response 62 Erythropoietic therapies may 62 microbiological eradication 62 BARACLUDE r 62 gadolinium enhancing lesions 62 HBeAg negative patients 62 lipid parameters 62 follicular lymphomas 62 HAMD 62 recurrent venous thromboembolism 62 Brief Psychiatric 62 receiving VICTRELIS 62 serum parathyroid hormone 62 inflammatory lesions 62 HbA 1c levels 62 NIHSS 62 IPSS 62 sUA 62 achieved CCyR 62 ALVESCO 61 serum IGF 61 COPD exacerbations 61 cEVR 61 Scale EDSS score 61 ADAS cog 61 serum urate levels 61 acromegalic patients 61 tipranavir r 61 relapsed MM 61 daunorubicin 61 alanine aminotransferase ALT 61 ACR# ACR# 61 FOLFIRINOX 61 demonstrated clinically meaningful 61 hematological adverse 61 peginterferon alfa 2a 61 Scale EDSS 61 Non inferiority 61 Disease Activity 61 serum phosphate 61 pulmonary exacerbations 61 EDSS score 61 laboratory abnormalities 61 recurrent VTE 61 macroalbuminuria 61 certolizumab 61 sulfasalazine 61 hip BMD 61 EDSS scores 61 HbA 1c 61 Rate ORR 61 ACTEMRA TM 61 Severity Index PASI 61 lopinavir r arm 61 CANCIDAS 61 PREZISTA r arm 61 clinically meaningful improvement 61 annualized relapse 61 FluCAM arm 61 CVD mortality 61 Doxil ® 61 ADAS Cog 61 CIMZIA TM certolizumab pegol 61 prednisone prednisolone 61 HBeAg positive patients 61 hematologic toxicity 61 symptomatic VTE 61 atherothrombotic disease 61 atherogenic dyslipidemia 61 mg kg belimumab 61 Hb A1C 61 p = NS 61 aminotransferases 61 receiving golimumab 61 sustained virologic response 61 CP CPPS 61 rosuvastatin #mg 61 complete cytogenetic 61 liver histology 61 HER2 overexpression 61 severe exacerbations 61 Expanded Disability Status 61 T2 lesions 60 GERD symptom 60 peripheral sensory neuropathy 60 steroid dexamethasone 60 affective psychosis 60 albumin excretion rate 60 suboptimal adherence 60 platelet reactivity 60 Lupuzor ™ 60 octreotide LAR 60 adenoma recurrence 60 sustained virological response 60 hemorrhagic complications 60 SGPT 60 nonvertebral fractures 60 pCR 60 CsA 60 TMC# r 60 chlorambucil 60 mRS 60 SGOT 60 Platelet counts 60 nighttime awakenings 60 HDRS 60 -#.# log# 60 Betaferon R 60 ARCALYST ® 60 imipenem 60 Flu Cy 60 bronchial hyperresponsiveness 60 thromboembolic 60 salivary cortisol 60 macrovascular events 60 intravascular hemolysis 60 % Confidence Interval 60 nondiabetic patients 60 thrombocytopenic 60 HBeAg seroconversion 60 morphometric vertebral fractures 60 canakinumab 60 hepatic enzymes 60 baseline A1C 60 elevated triglyceride levels 60 MACCE 60 symptom exacerbation 60 Primary endpoints 60 ATACAND 60 depressive symptom 60 receiving ISENTRESS 60 hemoglobin A1c HbA1c 60 placebo dexamethasone 60 ADCS CGIC 60 transaminases 60 adjunctive placebo 60 BMPR2 60 airway hyper responsiveness 60 ALT elevation 60 mcg QD 60 serum PTH 60 nitrotyrosine 60 certolizumab pegol 60 HOMA IR 60 Response Evaluation Criteria 60 SUVmax 60 BMI z 60 racemic albuterol 60 REYATAZ r arm 60 apo B 60 placebo p 60 MMSE scores 60 incontinence episodes 60 Hepatotoxicity 59 postoperative mortality 59 abdominal pain abdominal discomfort 59 HRQoL 59 nonfatal MI 59 IRLS score 59 clinicopathological 59 febrile neutropenia 59 UPDRS motor 59 colorectal adenoma 59 autoantibody positive 59 postdose 59 Secondary efficacy endpoints 59 DAS# scores 59 KRAS mutations occur 59 BARACLUDE ® 59 discontinuations due 59 metabolic parameters 59 placebo p = 59 antioxidant supplementation 59 hypovitaminosis D 59 apolipoprotein B 59 serum homocysteine 59 locoregional disease 59 PANSS 59 severe hypoglycemic 59 AST ALT 59 flow mediated dilation 59 T2DM 59 haematologic 59 HBeAg 59 perioperative mortality 59 SRBD 59 aldosterone antagonist 59 PCWP 59 8mg/kg 59 squamous histology 59 PSADT 59 CI -#.# 59 RLS symptoms 59 binary restenosis 59 6MWD 59 serum calcium levels 59 creatinine ratio 59 MARINOL R 59 moderate renal impairment 59 serum creatinine levels 59 CIPN 59 mg BID 59 bortezomib refractory 59 abdominal adiposity 59 WOMAC pain 59 tolvaptan 59 salmeterol fluticasone propionate 59 ruboxistaurin 59 EXJADE 59 PANSS total 59 ximelagatran 59 Secondary endpoints 59 CIN3 59 ARB telmisartan 59 plasma leptin 59 euthymic patients 59 patients evaluable 59 MACUGEN 59 SSRI SNRI 59 alicaforsen enema 59 elevated LDL cholesterol 59 psychopathological symptoms 59 β blockers 59 Montgomery Asberg Depression 59 NATRECOR R 59 solifenacin 59 STRIDE PD 59 rhinoconjunctivitis 59 International Prostate Symptom 59 symptom severity 59 tolterodine ER 59 mucosal inflammation 59 4mg/kg 59 NNT = 59 tamoxifen Nolvadex ® 59 FluCAM 59 cobiprostone 59 Pain Intensity 59 intracerebral haemorrhage 59 methotrexate monotherapy 59 gastrointestinal adverse reactions 59 elevated creatinine 59 ibandronate 59 paricalcitol 59 urinary calcium excretion 59 hormone receptor negative 59 glycated hemoglobin HbA1c 59 ALT flares 59 x ULN 59 RESIST studies 59 periprocedural 59 T1DM 59 atrophic gastritis 59 Operative mortality 59 autonomic dysfunction 59 FOLPI 59 microvascular complications 59 hemoglobin A1c levels 59 serum BDNF 59 glycosylated hemoglobin HbA1c 59 hematological parameters 59 hepatitis C genotype 59 mg kg dose 59 nephrotoxicity 59 CLA supplementation 59 chronic periodontitis 59 % CI #.#-#.# [007] 59 virological response 59 Ishak fibrosis score 58 â ‰ ¥ 58 intact parathyroid hormone 58 somatic symptoms 58 aminotransferase elevations greater 58 biologic DMARD 58 del 5q MDS 58 XIENCE V PROMUS Stent 58 decitabine 58 dose cytarabine 58 DMARD 58 achieved statistical significance 58 lymphopenia 58 dapagliflozin plus 58 TMP SMX 58 p = .# [001] 58 RECIST Response Evaluation Criteria 58 tapentadol IR 58 glomerular filtration 58 aspartate aminotransferase 58 HAM D# scores 58 TLUS 58 frequent awakenings 58 serum triglycerides 58 neutropenia thrombocytopenia 58 P = .# 58 Natalizumab 58 endoscopic remission 58 baseline LDH 58 concomitant medications 58 #mg/day [001] 58 EBMT criteria 58 Double Blind Randomized 58 intracranial hemorrhage ICH 58 serum clusterin levels 58 hematologic adverse 58 BEACOPP 58 Infusion Reactions Severe 58 Score DAS# 58 lymphocytosis 58 Ceplene/IL-2 58 highest tertile 58 Hematologic 58 rimonabant #mg 58 achieving PASI 58 achieved sustained virological 58 posttreatment 58 ACR# [002] 58 virologic failure 58 fluticasone salmeterol 58 mg TID 58 gout flare 58 diabetes mellitus DM 58 fasting plasma glucose FPG 58 IgG antibody 58 generalized edema 58 graft dysfunction 58 Exacerbations 58 univariate analyzes 58 timepoints 58 ADCS ADL 58 posaconazole 58 Unified Parkinson Disease 58 treatment emergent adverse 58 adalimumab Humira 58 nonvertebral fracture 58 highly emetogenic 58 somatostatin analog 58 ACZ# 58 seropositivity 58 dose pravastatin 58 urge urinary incontinence 58 baseline serum creatinine 58 postvaccination 58 Stent thrombosis 58 advanced adenoma 58 airway hyperresponsiveness 58 primidone 58 myeloperoxidase 58 INCB# [003] 58 mcg BID 58 CR CRu 58 Visual Analogue Scale VAS 58 systemic corticosteroid 58 plasma folate 58 viral titers 58 Viral load 58 HbA 1C 58 FOLFOX4 58 gout flares 58 antihypertensive therapy 58 myocardial reperfusion 58 Retreatment 58 ALT AST 58 piperacillin tazobactam 58 HPV-#/# 58 urinary oxalate 58 radiographic progression 58 clinicopathological features 58 DLTs 58 androgen suppression 58 multivariate adjustment 58 log# reduction 58 COPAXONE R 58 QTc prolongation 58 PsA 58 Ischemic 58 juvenile idiopathic arthritis JIA 58 left ventricular diastolic 58 atherogenic lipids 58 etanercept 58 Allergic Rhinitis 58 QTcF 58 pegylated interferon alfa 2b 58 reinfarction 58 microvessel density 58 CYP#A# substrate 58 NNRTI resistance 58 hypomagnesemia 58 MADRS 58 leucopenia 58 exploratory endpoints 58 ADHF 58 cytogenetic responses 58 ZOMIG Nasal Spray 58 thromboembolic disease 58 Timed Walk 58 Thrombocytopenia 58 neutrophil counts 58 hepatic cirrhosis 58 UPDRS scores 58 fasting insulin 58 urinary N telopeptide 58 hypophosphatemia 58 TAXUS Stent 58 Major Adverse Cardiac 58 paliperidone ER 58 interferon alfa 58 serum cortisol 58 visceral adiposity 58 SCr 58 Endothelial function 58 HDL LDL ratio 58 HER2 expression 58 mg QD 58 thyrotropin levels 57 myopathy rhabdomyolysis 57 elevated LDH 57 thyrotropin 57 preoperative chemotherapy 57 TIMP 1 57 apnea hypopnea 57 fasting plasma glucose 57 ispinesib administered 57 HAM D# 57 node metastases 57 IDDM 57 plus MTX 57 TNSS 57 UPDRS 57 prednisone prednisolone plus 57 Febrile neutropenia 57 chloride secretion 57 fatigue asthenia 57 Hazard Ratio 57 mmHg diastolic 57 hypokalemia 57 TNFalpha 57 venlafaxine XR 57 Cardiotoxicity 57 prostate cancer CaP 57 doxorubicin cyclophosphamide 57 elevated uric acid 57 elevated IOP 57 polyp recurrence 57 pulmonary capillary wedge 57 hypercalcemia 57 ALT elevations 57 inducible nitric oxide synthase 57 inotropic 57 biochemical relapse 57 ARCOXIA 57 serum uric acid 57 glycosylated hemoglobin 57 antibody titer 57 postprandial insulin 57 linaclotide treated 57 neurologic complications 57 REMINYL ® 57 LANTUS ® 57 neurocognitive function 57 #.#/#.# mmHg [001] 57 Celsentri Selzentry 57 MetS 57 titrated glipizide 57 Nilotinib 57 SGRQ 57 elevated serum creatinine 57 clinically meaningful improvements 57 EMBLEM TM 57 mycophenolate mofetil 57 pruritus itching 57 cerebrovascular events 57 hepatic insulin sensitivity 57 hyperalgesia 57 achieved PASI 57 adenotonsillectomy 57 dermatologic toxicities 57 PegIFN RBV 57 LUTS 57 nonfatal myocardial infarction MI 57 proliferative diabetic retinopathy 57 quetiapine XR 57 mg ustekinumab 57 infliximab therapy 57 #q# deletion syndrome 57 calculated creatinine clearance 57 serum lipid levels 57 Zometa hazard 57 inhaled budesonide 57 serum aminotransferase levels 57 sargramostim 57 HeFH 57 Cipralex ® 57 refractory AML 57 TNF antagonist 57 pharmacokinetic PK profile 57 thromboembolic events 57 mcg Albuferon 57 nonvertebral 57 bosentan 57 % CI #.#-#.# [003] 57 virologic 57 CYPHER Stent 57 oral FTY# 57 carotid IMT 57 invasive aspergillosis 57 interleukin IL -6 57 mean baseline A1C 57 IRLS 57 NPH insulin 57 doripenem 57 pharmacodynamic PD 57 nonfasting triglycerides 57 Helicobacter pylori infection 57 -5 -6 57 postoperative atrial fibrillation 57 Ocular Surface Disease 57 hypercholesterolaemia 57 GOUT 57 familial AF 57 HMG CoA reductase inhibitors 57 invasive ductal 57 BENICAR HCT 57 oral allopurinol 57 dose dependently 57 Subgroup analyzes 57 aldosterone antagonists 57 ABC/3TC 57 Drug eluting stent 57 neutropenic fever 57 virologic responses 57 zolmitriptan 57 Thal Dex 57 extrapyramidal side 57 hyperhomocysteinemia 57 HbA1c levels 57 chronic prostatitis 57 isoproterenol 57 ARIXTRA 57 prolonged QT interval 57 nadroparin 57 receiving APTIVUS r 57 glycosylated hemoglobin levels 57 lipid lowering agents 57 urinary albumin 57 paraprotein 57 plus dexamethasone 57 cardiac autonomic 57 severe asthma exacerbations 57 Nocturia 57 #mg/day [002] 57 IFN α 57 Virologic failure 57 endometrial hyperplasia 57 mL/min/#.# m 2 57 μmol L 57 leukocyte count 57 prolactin levels 57 periprocedural MI 57 UACR 57 neurodevelopmental impairment 57 mcg albinterferon alfa 2b 57 glycemic variability 57 sputum eosinophils 57 HSCT 57 SPRYCEL ® 57 TAXUS Express Stent 57 FDG uptake 57 Score IPSS 57 virologic failures 57 fosamprenavir 57 subclinical atherosclerosis 57 Teriflunomide 57 bronchopulmonary dysplasia 57 serum leptin 57 perioperative complications 57 DLQI 57 scintigraphic 57 + PH# 57 alemtuzumab treated 57 virologic breakthrough 57 CombAT 57 advanced adenomas 57 depressive symptomatology 57 nonsignificant 57 Folfox 57 heavily pretreated 57 cabazitaxel 57 lymphovascular invasion 57 URTI 57 log# copies mL 57 HRCT 57 troponin T 57 mutated KRAS 57 MoxDuo TM IR 57 peginterferon 57 venous thromboembolic disease 57 caspofungin 57 demyelinating 57 cardiometabolic risk 57 mucosal healing 57 recurrent glioblastoma multiforme 57 autoantibody levels 57 subscale scores 57 teriparatide 57 statistically nonsignificant 57 IFN beta 57 aspartate aminotransferase AST 57 Univariate analysis 57 atypical ductal hyperplasia 57 albuminuria 57 atherothrombotic 57 treat NNT 57 L PPDS 57 secondary endpoint 57 gemifloxacin 57 serum potassium 57 corticosteroid therapy 57 liver enzymes ALT 57 affective psychoses 57 Severe Asthma 57 uM 57 KRAS mutant tumors 57 Hypotension 57 CFQ R 57 intravenous bisphosphonates 57 TAXUS p value 57 atorvastatin #mg 57 glulisine 57 hyperglycaemia 57 eplerenone 57 macrovascular 57 HRQOL 57 axillary node 57 urate lowering therapy 57 INC# 57 serum sodium levels 57 fibrosis progression 57 serum ALT 57 multivariate analyzes 57 ecchymosis 56 intestinal permeability 56 pegylated interferon alfa 56 lispro 56 APTIVUS 56 postoperative AF 56 NQO1 56 Nonresidential structures 56 lymphocyte counts 56 cardiac dysfunction 56 teriflunomide 56 blood Phe levels 56 TNF α 56 FFNS 56 asymptomatic carotid stenosis 56 dasatinib 56 Nesiritide 56 pegylated IFN 56 RAPAFLO R 56 retinal thickness 56 Atopic Dermatitis 56 Dyspnea 56 CTEPH 56 CHD mortality 56 metachronous 56 SVR# 56 confidence interval #.#-#.# 56 follicular lymphoma FL 56 STN stimulation 56 MIC# [001] 56 atherosclerotic vascular disease 56 tipranavir 56 neurologic impairment 56 symptomatic intracranial hemorrhage 56 nadolol 56 histologies 56 clodronate 56 AA Amyloidosis 56 postintervention 56 OSAHS 56 symptomatic intracranial 56 intensive statin therapy 56 variceal bleeding 56 VaD 56 apnea hypopnea index 56 permanently discontinue Vectibix 56 CPAP adherence 56 urine albumin 56 See CLINICAL PHARMACOLOGY 56 PSA kinetics 56 Etanercept 56 cTnT levels 56 Solid Tumors 56 p = .# [002] 56 SSc 56 HER2 positivity 56 incidence ≥ 56 coronary stenosis 56 tamsulosin 56 airway hyper 56 micafungin 56 Decitabine 56 serum phosphate levels 56 5-FU/LV 56 myeloproliferative neoplasms 56 univariate analysis 56 subscore 56 aspirin clopidogrel 56 lipohypertrophy 56 flutamide 56 plasma lipid 56 Ejection Fraction 56 salivary flow 56 lymphoma subtypes 56 esophageal squamous cell carcinoma 56 dosing frequency 56 QIDS SR 56 severe neutropenia 56 androgen depletion therapy 56 dose atorvastatin 56 pressure natriuresis 56 timepoint 56 osteoclastic 56 LEXIVA r 56 Scale cognitive subscale 56 Events MACE 56 vWF 56 LPS induced 56 tolerability profiles 56 oesophageal adenocarcinoma 56 GnRH agonists 56 SPIRIVA ® 56 plasma HCV RNA 56 interferon γ 56 Tumor shrinkage 56 Pharmacokinetic parameters 56 S. aureus isolates 56 lactate dehydrogenase 56 peginterferon alfa 2a #KD 56 Fasting blood glucose 56 hydroxyvitamin D levels 56 interferon beta therapy 56 adjunctive ABILIFY 56 clinically meaningful reductions 56 % CI #.#-#.# [005] 56 urine NGAL 56 hypoperfusion 56 PRADAXA 56 pulmonary dysfunction 56 dose Iluvien 56 nasal symptom 56 CK # plasma concentrations 56 FACIT Fatigue 56 mIU L 56 coronary calcification 56 cytopenias 56 proinflammatory cytokine 56 ertapenem 56 juvenile idiopathic arthritis 56 histological subtype 56 selective modulator 56 Pred Forte 56 Venous thromboembolism 56 HUMIRA achieved PASI 56 hematological toxicities 56 progression TTP 56 hallucinations dyskinesia 56 external genital lesions 56 Omiganan 56 immunoreactivity 56 Pioglitazone 56 reflux symptoms 56 PANSS scores 56 glycemia 56 serum sodium 56 nonsignificant difference 56 probiotic supplementation 56 triglyceride concentrations 56 triacylglycerol 56 log# 56 cinacalcet 56 hyperoxaluria 56 HbA1C 56 Visual acuity 56 confidence intervals CIs 56 Leukemias 56 H2RAs 56 antiarrhythmic drug 56 tic severity 56 NAbs 56 postoperative pulmonary 56 CYT# potent vascular disrupting 56 echocardiographic parameters 56 PSA nadir 56 atazanavir ritonavir 56 overactive bladder symptoms 56 serum phosphorous 56 comorbid anxiety 56 growth hormone secretion 56 STELARA 56 albumin excretion 56 Pegasys ® 56 mg/m2 dose 56 serum HCV RNA 56 glycated hemoglobin 56 angiographic outcomes 56 oral diclofenac 56 ritonavir boosted 56 evaluating tivozanib 56 Juvenile Idiopathic Arthritis 56 lumbar spine bone 56 Non Responders 56 fluconazole resistant 56 serum PSA 56 carotid stenosis 56 idraparinux 56 rFVIIa 56 euthymic 56 triacylglycerol concentrations 56 Hematologic toxicity 56 GSTP1 56 vasomotor symptoms 56 Vidofludimus 56 lymphocyte count 56 experienced virologic failure 56 erythropoietic 56 CIN2 + 56 serum retinol 56 infliximab etanercept 56 PNH patients 56 fasting glucose levels 56 baseline FEV 56 tumor regressions 56 arthralgias 56 estimated glomerular filtration 56 oblimersen 56 Engerix B 56 VIIBRYD 56 mCi kg 56 MS relapses 56 multivariate Cox 56 erythrocyte sedimentation rate 56 pulmonary exacerbation 56 serum triglyceride levels 56 aromatase inhibitors AIs 56 linear pharmacokinetics 56 Virologic 56 HDL Cholesterol 56 chronic prostatitis chronic 56 isolated systolic hypertension 56 Serum creatinine 56 Knodell necroinflammatory score 56 Alzheimer Disease Assessment 56 K ras mutations 56 ANCOVA 56 plus aztreonam 56 Fibromyalgia Impact Questionnaire 56 Insulin sensitivity 56 renal cell carcinomas 56 FRAGMIN 56 dysmenorrhea 56 YERVOY 56 subtrochanteric 56 hsCRP levels 56 Renal impairment 56 FAMPYRA 56 Adalimumab 56 serum antibody 56 femoral neck BMD 56 pyrexia mucositis sepsis febrile 56 Interferon Beta 56 microalbuminuria 56 thrombolytic agents 56 MMSE score 56 tumor necrosis 56 Chronic Obstructive Lung 56 Score TOS 56 gastric pH 56 Renal dysfunction 56 blood Phe 56 viral kinetics 56 pegylated liposomal doxorubicin 56 Health Assessment Questionnaire 56 Physical Component 56 tocilizumab 56 antibody titers 56 inhospital mortality 55 multivariable adjusted 55 ‰ ¥ 55 paresthesias 55 secondary efficacy endpoints 55 adverse cytogenetics 55 thrombotic events 55 nonadherence 55 fludarabine cyclophosphamide 55 recurrent genital herpes 55 estimated GFR 55 INTEGRILIN 55 subjective sleepiness 55 PRADAXA #mg 55 conjunctival hyperemia 55 hyperphenylalaninemia HPA due 55 oxygen desaturation 55 AGILECT R 55 interferon ribavirin 55 pegylated interferon alpha 55 ocular toxicity 55 subscales 55 balsalazide 55 imatinib therapy 55 Follicular Lymphoma 55 Heavy menstrual bleeding 55 lactate dehydrogenase LDH 55 tumor histology 55 histologic subtypes 55 arterial calcification 55 prospectively defined 55 POAG 55 tirofiban 55 Hycamtin ® 55 dyspnea 55 beta carotene supplementation 55 salmeterol fluticasone 55 psychiatric comorbidities 55 serum phosphorus 55 spirometric 55 coinfected patients 55 erection hardness